Compare Organon Pharma Indonesia Tbk. (SCPI) vs Solusi Bangun Indonesia Tbk. (SMCB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Solusi Bangun Indonesia Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Solusi Bangun Indonesia Tbk. trades at Rp775 (market cap 6.99T). The key difference: Solusi Bangun Indonesia Tbk. is far larger — about 67× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMCB | |
|---|---|---|
Market Cap | 104.4B | 6.99T |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Solusi Bangun Indonesia Tbk.
PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.
Read more on SMCB →
